Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants [Yahoo! Finance]
Anixa Biosciences, Inc. (ANIX)
Last anixa biosciences, inc. earnings: 3/9 05:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
Combination of Keytruda ® and the vaccine generated T cell responses and showed no major additional side effects, supporting plans for a Phase 2 neoadjuvant combination study in newly diagnosed breast cancer patients SAN JOSE, Calif. Dec. 11, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced the presentation of final data from the Phase 1 clinical trial of its investigational breast cancer vaccine ( NCT04674306 ) at the 2025 San Antonio Breast Cancer Symposium (SABCS). The trial was conducted in collaboration with Cleveland Clinic and funded by a grant from the U.S. Department of Defense. Final Phase 1 findings showed the investigational vaccine met all major primary endpoints, was safe and well tolerated at the maximum tolerated dose (MTD), and elicited protocol-defined immune responses in 74% of participants. The presentation, titled "Final Results of
Show less
Read more
Impact Snapshot
Event Time:
ANIX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANIX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANIX alerts
High impacting Anixa Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
ANIX
News
- Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic [Yahoo! Finance]Yahoo! Finance
- Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland ClinicPR Newswire
- Anixa Biosciences (NASDAQ:ANIX) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.MarketBeat
- Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of ParticipantsPR Newswire
- Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025PR Newswire
ANIX
Earnings
- 9/10/25 - Beat
ANIX
Sec Filings
- 12/12/25 - Form 8-K
- 10/31/25 - Form 4
- 10/1/25 - Form EFFECT
- ANIX's page on the SEC website